Wright J C
J Natl Med Assoc. 1986 May;78(5):395-408.
An update of the state of the art of cancer chemotherapeutic treatment of gastrointestinal tract cancer is described in a multi-part series. Part 1 surveyed colorectal cancer and the use of single-agent chemotherapy in the April issue of the Journal. Part 2 of colorectal cancer will describe combination chemotherapy, preoperative and postoperative radiation, and combinations of chemotherapy and radiation, and adjuvant chemotherapy.In advanced gastrointestinal tract cancer, chemotherapy is only of palliative value with response rates generally under 50 percent and survival rates of several months to one year or more. Combination chemotherapy often produces higher response rates, yet there is no acceptable evidence that survival is improved. While some adjuvant chemotherapy trials suggest improvement, major survival gains remain to be demonstrated. Uncertainty as to the role of chemotherapy in the treatment of gastrointestinal cancers may be due to lack of data.
一个多部分系列文章描述了胃肠道癌化学治疗的最新技术水平。第1部分在《杂志》4月刊中调查了结直肠癌和单药化疗的使用情况。结直肠癌的第2部分将描述联合化疗、术前和术后放疗,以及化疗与放疗的联合应用,还有辅助化疗。在晚期胃肠道癌中,化疗仅具有姑息价值,缓解率一般低于50%,生存率为几个月至一年或更长时间。联合化疗通常能产生更高的缓解率,但尚无可接受的证据表明生存率有所提高。虽然一些辅助化疗试验表明有改善,但主要的生存获益仍有待证实。化疗在胃肠道癌治疗中的作用存在不确定性可能是由于缺乏数据。